[1] |
Ciborowski P, Finn OJ. Non-glycosylated tandem repeats of MUC1 facilitate attachment of breast tumor cells to normal human lung tissue and immobilized extracellular matrix proteins (ECM) in vitro: potential role in metastasis [J]. Clin Exp Metastasis, 2002, 19(4): 339-45.
|
[2] |
Ren G,Yu G,Liu LW,et al.Expression and significance of MUC1 in gallbladder carcinoma[J].Zhong Liu Fang Zhi Yan Jiu,2009,36(10):844-6.[任刚,于国,刘丽威,等.MUC1蛋白在胆囊癌中的表达及其意义[J].肿瘤防治研究,2009,36(10):844-6.]
|
[3] |
Yi HY, Xie YQ, Li Y, et al. The strongly positive expression of MUC1 in ER-positive breast cancer tissues and the relationship between MUC1 and prognosis of breast cancer[J]. Zhongguo Ai Zheng Za Zhi, 2011,21(2): 115-9.[裔海鹰,谢轶群,李圆,等.ER阳性乳腺癌中MUC1的强阳性表达及其与预后的关系[J].中国癌症杂志,2011,21(2): 115-9.]
|
[4] |
Kondo K, Kohno N, Yokoyama A, et al. Decreased MUC1 expression induces E-cadherin-mediated cell adhesion of breast cancer cell lines[J]. Cancer Res, 1998, 58(9): 2014-9.
|
[5] |
Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer[J]. J Clin Oncol, 2010, 28(16): 2784-95.
|
[6] |
Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer [J]. Arch Pathol Lab Med, 2007, 131(1): 18-43.
|
[7] |
Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study[J]. JAMA, 2006, 295(21): 2492-502.
|
[8] |
Schroeder JA, Thompson MC, Gardner MM, et al. Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland [J]. J Biol Chem, 2001, 276(16): 13057-64.
|
[9] |
Bensouda Y, Andr F, Boulet T, et al. Prevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status[J]. Bull Cancer, 2009, 96(10): 923-8.
|
[10] |
Kufe D, Inghirami G, Abe M, et al. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors[J]. Hybridoma, 1984, 3(3): 223-32.
|
[11] |
Baldus SE, Wienand JR, Werner JP, et al. Expression of MUC1, MUC2 and oligosaccharide epitopes in breast cancer: prognostic significance of a sialylated MUC1 epitope[J]. Int J Oncol, 2005, 27(5): 1289-97.
|
[12] |
Arvold ND, Taghian AG, Niemierko A, et al. Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy[J]. J Clin Oncol,2011, 29(29): 3885-91.
|
[13] |
Tantivatana T, Chongthanakorn M, Rongsriyam K, et al. Treatment outcomes and prognostic factors of patients with breast cancer: a retrospective review[J]. J Med Assoc Thai,2009, 92(8): 1084-93.
|
[14] |
Chen XS, Ma CD, Wu JY, et al. Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer[J]. Tumori,2010, 96(1): 103-10.
|
[15] |
Wei X, Xu H, Kufe D.MUC1 oncoprotein stabilizes and activates estrogen receptor alpha[J]. Mol Cell, 2006, 21(2): 295-305.
|
[16] |
Khodarev N, Ahmad R, Rajabi H, et al. Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer [J]. Oncogene, 2010, 29(6): 920-9.
|
[17] |
Khodarev NN, Pitroda SP, Beckett MA, et al.MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment [J]. Proc Natl Acad Sci U S A, 2009, 106(14): 5837-41.
|
[18] |
Fessler SP, Wotkowicz MT, Mahanta SK, et al. MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells[J]. Breast Cancer Res Treat,2009, 118(1): 113-24.
|
[19] |
Cheng JP, Yan Y, Wang XY, et al. MUC1-positive circulating tumor cells and MUC1 protein predict chemotherapeutic efficacy in the treatment of metastatic breast cancer[J]. Chin J Cancer,2011, 30(1): 54-61.
|